The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Ann Sing Lee
Research Funding - Aegera Therapeutics
Benny C.Y. Zee
Research Funding - Chinese University of Hong Kong
Foon Yiu Cheung
Research Funding - Aegera Therapeutics
Philip Kwong
Research Funding - Aegera Therapeutics
Ashley Chi Kin Cheng
Research Funding - Aegera Therapeutics
Maria Lai
Research Funding - Aegera Therapeutics
Chloe Kwok
Research Funding - Aegera Therapeutics
Marc Chong
Research Funding - Aegera Therapeutics
Jacques Jolivet
Employment or Leadership Position - Aegera Therapeutics
Consultant or Advisory Role - Pharmascience
Stock Ownership - Aegera Therapeutics
Expert Testimony - Aegera Therapeutics
Other Remuneration - Aegera Therapeutics
C L Chiang
Research Funding - Aegera Therapeutics
K C Leung
Research Funding - Aegera Therapeutics
Steven Siu
Research Funding - Aegera Therapeutics
Conrad Lee
Research Funding - Aegera Therapeutics
Stewart Yuk Tung
Research Funding - Aegera Therapeutics; Aegera Therapeutics